Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alcon Research |
---|---|
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00061516 |
To evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.
Condition | Intervention | Phase |
---|---|---|
Glaucoma Ocular Hypertension |
Drug: BETAXON (levobetaxolol HCl) Drug: AZOPT (brinzolamide) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension |
Ages Eligible for Study: | up to 5 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION:
EXCLUSION:
Study ID Numbers: | C-00-17 |
Study First Received: | May 28, 2003 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00061516 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Glaucoma Ocular Hypertension |
Carbonic Anhydrase Inhibitors Brinzolamide Glaucoma Eye Diseases |
Vascular Diseases Hypertension Ocular Hypertension |
Carbonic Anhydrase Inhibitors Molecular Mechanisms of Pharmacological Action Brinzolamide Glaucoma Eye Diseases Vascular Diseases |
Enzyme Inhibitors Cardiovascular Diseases Pharmacologic Actions Ocular Hypertension Hypertension |